CTIS.EU
LightNews LightNews
ctiseu.bsky.social
CTIS.EU
@ctiseu.bsky.social
0 followers 1 following 7 posts
Posts Replies Media Videos
ctiseu.bsky.social
Novo Nordisk A/S this week in the EU register: 2 new trials authorised, 3 trials started recruitment, 1 summary of results posted, 1 summary for laypersons posted.

https://ctis.eu/sponsors/novo-nordisk-a-s
#ClinicalTrials
Novo Nordisk A/S | CTIS.eu
Trials of Novo Nordisk A/S in the public EU register
ctis.eu
October 30, 2026 at 1:13 PM
ctiseu.bsky.social
Summary of the results posted: phase II trial of pembrolizumab, vibostolimab in non-Muscle Invasive Bladder Cancer in 7 EU/EEA countries. Sponsor: Merck Sharp & Dohme LLC. 254 participants planned.

https://ctis.eu/trial/2022-502526-41-00
#ClinicalTrials #Oncology
Pembrolizumab (MK-3475) and pembrolizumab in combination with other investigational agents in high risk NMIBC patients unresponsive to BCG
Trial record 2022-502526-41-00 in the public EU register, on CTIS.eu
ctis.eu
October 29, 2026 at 11:39 AM
ctiseu.bsky.social
Newly authorised: phase III trial of bevacizumab in Ovarian Neoplasms in 4 EU/EEA countries. Sponsor: Glaxosmithkline Research & Development Limited. 423 participants planned.

https://ctis.eu/trial/2025-523366-24-00
#ClinicalTrials #Oncology
A study to investigate mocertatug rezetecan with bevacizumab compared with platinum doublet with bevacizumab in participants with platinum-sensitive ovarian cancer.
Trial record 2025-523366-24-00 in the public EU register, on CTIS.eu
ctis.eu
October 29, 2026 at 7:49 AM
ctiseu.bsky.social
Newly authorised: phase II/III trial of zimislecel in type 1 Diabetes Mellitus with Impaired Hypoglycemic… in 5 EU/EEA countries. Sponsor: Vertex Pharmaceuticals Inc. 36 participants planned.

https://ctis.eu/trial/2024-513929-23-00
#ClinicalTrials #Diabetes
A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX- 880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia
Trial record 2024-513929-23-00 in the public EU register, on CTIS.eu
ctis.eu
October 28, 2026 at 9:07 AM
ctiseu.bsky.social
Newly authorised: phase III trial of ritlecitinib tosilate in moderate alopecia areata in 2 EU/EEA countries. Sponsor: Pfizer Inc. 246 participants planned.

https://ctis.eu/trial/2026-526355-62-00
A study in young people and adults to learn about the medicine ritlecitinib for treatment of patchy hair loss, known by the medical term as moderate alopecia areata
Trial record 2026-526355-62-00 in the public EU register, on CTIS.eu
ctis.eu
October 27, 2026 at 2:37 PM
ctiseu.bsky.social
Summary of the results posted: phase II trial of AUP1602-C in diabetic foot ulcers in 3 EU/EEA countries. Sponsor: Aurealis Oy.

https://ctis.eu/trial/2022-502048-10-00
A phase-2, multi-centre, prospective, randomized, standard-of-care plus placebo-controlled, patient and central evaluator blinded, parallel arm, clinical study to evaluate safety, tolerability and efficacy of the recommended phase-2 dose of AUP1602-C in two dosing frequencies as a…
Trial record 2022-502048-10-00 in the public EU register, on CTIS.eu
ctis.eu
October 27, 2026 at 12:54 PM
ctiseu.bsky.social
EU clinical trials, week 43 of 2026: 74 new trials authorised, 60 trials started recruitment, 13 trials ended, 4 of them early.

https://ctis.eu/news/brief/2026-W43
#ClinicalTrials #EUCTR
EU clinical trials, week 43 of 2026: 74 new trials authorised, 4 trials ended early
In week 43 of 2026 (19 to 25 October), the public EU register of clinical trials showed 74 newly authorised trials. Recruitment started in 60 trials (69 country starts in total) and ended in 22 trials. 17 ongoing trials added at least one country. The largest new trial by planned…
ctis.eu
October 27, 2026 at 9:21 AM